Approaches targeting K(V)10.1 open a novel window for cancer diagnosis and therapy.
K(V)10.1 has recently become generally accepted as a promising cancer target, as it is ectopically expressed in the majority of solid tumors. Due to its cell-surface accessibility, K(V)10.1 has a strong potential for tumor treatment and diagnosis. Given that its mode of action is likely independent of conventional cancer pathways such as tyrosine kinases, K(V)10.1 opens a novel window for treating cancer. In this review we will give an overview of the current status of data linking K(V)10.1 to cancer, and propose techniques that could exploit K(V)10.1's properties for the management of cancer.
Max-Planck-Institute of Experimental Medicine, Hermann-Rein-Str. 3, 37075 Göttingen, Germany. pardo@em.mpg.de
L A
LA
Pardo
D
D
Gómez-Varela
F
F
Major
K
K
Sansuk
R
R
Leurs
B R
BR
Downie
L F
LF
Tietze
W
W
Stühmer
D051638:Ether-A-Go-Go Potassium Channels / Q000627:therapeutic use*; D006801:Humans; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000175:diagnosis / Q000628:therapy
D051638:Ether-A-Go-Go Potassium Channels; C496884:KCNH1 protein, human